Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.84 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.84 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.84 |
| ▸ | PRKACA | P17612 | 2/20 | 0.84 |
| ▸ | PRKACG | P22612 | 2/20 | 0.84 |
| ▸ | PRKACB | P22694 | 2/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825773 | 0.91 | BLM (0.84) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL7521869 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29381357 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL7950989 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29478506 | 0.89 | BLM (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29399288 | 0.89 | BLM (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29379210 | 0.83 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29358957 | 0.83 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29393590 | 0.83 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL30028991 | 0.83 | MAPT (0.63) | PDE4APDE4BPDE4CPDE4DPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | PDE4A 2291/4885PDE4B 1941/4885PDE4C 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.